BERNARD MICHLIN: Open Payments
NPI 1861492738 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,911 in 184 payments from 40 companies in 2025. Trend: 2023 $6,090 · 2024 $4,781 · 2025 $3,911
Food & beverage: $3,869Education: $43
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 16 | $534 |
| UCB, Inc. | 22 | $309 |
| Neurocrine BioSciences, Inc. | 7 | $261 |
| ABBVIE INC. | 14 | $234 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $216 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $205 |
| Axsome Therapeutics, Inc. | 4 | $193 |
| PFIZER INC. | 14 | $145 |
| AstraZeneca Pharmaceuticals LP | 8 | $143 |
| Neurelis, Inc. | 16 | $140 |
Products named: FANAPT, INGREZZA, CAPLYTA, Kerendia, Auvelity, VRAYLAR, Fintepla, VALTOCO.
Industry payments across CA — which companies pay providers there.
